Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Non-Interventional Study on Edoxaban Treatment in Routine Clinical Practice for Patients With Non Valvular Atrial Fibrillation

Next Previous
Trial Profile

Non-Interventional Study on Edoxaban Treatment in Routine Clinical Practice for Patients With Non Valvular Atrial Fibrillation

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 04 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Edoxaban (Primary)
  • Indications Cardiovascular disorders; Embolism; Embolism and thrombosis; Stroke
  • Focus Adverse reactions
  • Acronyms ETNA-AF-EU; ETNA-AF-Europe
  • Sponsors Daiichi Sankyo Company; Daiichi Sankyo Inc

Most Recent Events

  • 02 Sep 2024 Results (n=13164) assessing the baseline characteristics and rates of any thromboembolic and hemorrhagic events per 100 patient-years using 4-year follow-up data, presented at the ESC Congress 2024 - Annual Congress of the European Society of Cardiology
  • 28 Aug 2023 Results (n=13164) assessing long-term effectiveness and safety of edoxaban in patients with atrial fibrillation presented at the ESC Congress 2023 - Annual Congress of the European Society of Cardiology
  • 28 Aug 2023 Results of sub analysis assessing of perceived versus objective frailty on outcome events in patients with AF treated with edoxaban during the 4-year follow-up of the ETNA-AF-Europe registry presented at the ESC Congress 2023 - Annual Congress of the European Society of Cardiology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top